```html

Uveitis Secondary to Autoimmune Disease – A Comprehensive Patient Guide

Overview

Uveitis is inflammation of the uveal tract, the middle layer of the eye that includes the iris, ciliary body, and choroid. When uveitis occurs as a result of an underlying autoimmune disease—such as ankylosing spondylitis, Behçet’s disease, sarcoidosis, or rheumatoid arthritis—it is called uveitis secondary to autoimmune disease.

• Who it affects: Adults ages 20‑50 are most commonly diagnosed, but children with juvenile idiopathic arthritis (JIA) can also develop this form.
• Prevalence: Uveitis accounts for ~10% of all blindness worldwide. Approximately 30–40% of uveitis cases are linked to systemic autoimmune conditions (Mayo Clinic, 2023).

The condition can involve one eye (unilateral) or both eyes (bilateral) and may be acute (sudden onset, lasting days to weeks) or chronic (lasting months to years). Prompt recognition is essential because inflammation can damage structures vital for vision.

Symptoms

Symptoms may vary depending on the part of the uveal tract involved (anterior, intermediate, posterior, or panuveitis). Common manifestations include:

Anterior uveitis (iritis/iridocyclitis)

• Redness at the white of the eye, often centered around the iris.
• Eye pain that worsens with bright light (photophobia).
• Blurred or decreased vision.
• Tearing and a gritty sensation.
• Small or irregular pupil (due to spasm of the iris sphincter).

Intermediate uveitis (pars planitis)

• Floaters (tiny specks or cobwebs drifting in the visual field).
• Mild to moderate eye pain.
• Peripheral vision loss in severe cases.
• Occasional mild redness.

Posterior uveitis (choroiditis, retinitis, vasculitis)

• Sudden loss of central vision or “black spot” in the visual field.
• Distorted vision (metamorphopsia).
• Floaters and flashes of light.
• Redness is usually minimal.

Panuveitis (inflammation of all uveal layers)

• Combination of the symptoms above.
• Severe redness, pain, photophobia, and vision loss.

Because symptoms can overlap with other eye conditions (conjunctivitis, glaucoma, cataract), a professional eye exam is essential for accurate diagnosis.

Causes and Risk Factors

Autoimmune-driven uveitis occurs when the immune system mistakenly attacks eye tissues, either directly or via circulating immune complexes.

Common autoimmune diseases linked to uveitis

• Ankylosing spondylitis (AS): Up to 40% of AS patients develop anterior uveitis (NIH, 2022).
• Behçet’s disease: Characterized by recurring oral/genital ulcers and can cause severe posterior uveitis.
• Sarcoidosis: Granulomatous inflammation often involves the posterior segment.
• Rheumatoid arthritis (RA): Typically associated with chronic, bilateral anterior uveitis.
• Juvenile idiopathic arthritis (JIA): The most common cause of uveitis in children.
• Inflammatory bowel disease (IBD): Particularly ulcerative colitis and Crohn’s disease.

Risk factors

• Genetic predisposition (HLA‑B27 positivity increases risk for AS‑related uveitis).
• Family history of autoimmune disease.
• Female sex for JIA‑related uveitis; male sex for AS‑related uveitis.
• Smoking – linked to more severe inflammatory eye disease.
• Delayed treatment of the underlying systemic disease.

Diagnosis

Diagnosing uveitis secondary to autoimmune disease requires a combination of detailed history, eye examination, and systemic work‑up.

Ophthalmic evaluation

1. Visual acuity test – baseline measurement of vision.
2. Slit‑lamp biomicroscopy – visualizes inflammation in the anterior segment.
3. Fundus examination (indirect ophthalmoscopy) – assesses posterior segment involvement.
4. Intra‑ocular pressure (IOP) measurement – inflammation or steroid use can raise IOP.
5. Fluorescein angiography or indocyanine green angiography – highlights retinal or choroidal vasculitis.
6. Optical coherence tomography (OCT) – cross‑sectional imaging of retina and macula, useful for monitoring edema.

Systemic work‑up

• Complete blood count (CBC) and inflammatory markers (ESR, CRP).
• Serologic tests: HLA‑B27, ANA, RF, anti‑CCP, and specific antibodies for diseases like Behçet’s (pathergy test) or sarcoidosis (ACE level).
• Imaging: Chest X‑ray or CT for sarcoidosis, MRI of sacroiliac joints for AS.
• Referral to rheumatology or gastroenterology for coordinated care.

Diagnostic criteria

Uveitis is classified by anatomic location (anterior, intermediate, posterior, panuveitis) and by activity (active vs. inactive) per the Standardization of Uveitis Nomenclature (SUN) Working Group.

Sources: SUN Working Group, *Ophthalmology* 2022; Mayo Clinic. “Uveitis” 2023.

Treatment Options

Treatment aims to control inflammation, preserve vision, and address the underlying autoimmune disease. Therapy is usually individualized based on severity, anatomic location, and systemic health.

Medications

• Topical corticosteroids (e.g., prednisolone acetate 1%): First‑line for mild anterior uveitis. Frequency tapered as inflammation resolves.
• Cycloplegic agents (e.g., atropine, cyclopentolate): Relieve pain from ciliary spasm and prevent posterior synechiae.
• Systemic corticosteroids (oral prednisone 0.5–1 mg/kg): Used for intermediate, posterior, or severe anterior uveitis, or when rapid control is needed.
• Immunomodulatory therapy (IMT) – “steroid‑sparing” agents:
  • Antimetabolites: Methotrexate, mycophenolate mofetil, azathioprine.
  • T-cell inhibitors: Cyclosporine, tacrolimus.
  • Biologic agents: Adalimumab (Humira) is FDA‑approved for non‑infectious uveitis; infliximab, secukinumab, and ustekinumab are used off‑label.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – oral or topical NSAIDs can help mild cases, but are less effective than steroids.

Procedures

• Periocular or intravitreal steroid injection (triamcinolone, dexamethasone implant) for refractory posterior uveitis.
• Immunosuppressive biologic infusions (e.g., infliximab) administered in a hospital setting.
• Laser photocoagulation for retinal neovascularization secondary to chronic inflammation.
• Surgery (e.g., cataract extraction, glaucoma filtering surgery) may be required after inflammation is controlled.

Lifestyle & supportive measures

• Protect eyes from bright light with sunglasses (UV‑400).
• Regular use of lubricating eye drops to prevent dryness.
• Adherence to systemic disease therapy (e.g., disease‑modifying anti‑rheumatic drugs for RA).
• Smoking cessation and balanced nutrition rich in omega‑3 fatty acids (anti‑inflammatory).

Sources: American Academy of Ophthalmology (AAO) Uveitis Guidelines 2023; CDC “Behçet’s Disease” 2022; FDA label for adalimumab 2021.

Living with Uveitis Secondary to Autoimmune Disease

Daily management tips

• Medication calendar: Keep a written or app‑based schedule for eye drops and systemic meds; set reminders for tapering.
• Regular eye exams: At least every 3–4 months while active, or as directed by your ophthalmologist.
• Monitor vision changes: Use a simple “A‑chart” at home to detect subtle declines; report any new floaters, flashes, or loss of vision promptly.
• Protect against infection: Avoid touching eyes with dirty hands; disinfect contact lenses and cases if you wear them.
• Manage systemic disease: Keep rheumatology or gastroenterology appointments, take prescribed disease‑modifying drugs, and track disease activity scores.
• Stress reduction: Stress can exacerbate autoimmune flares; incorporate relaxation techniques (mindfulness, yoga).
• Support networks: Join patient groups (e.g., National Eye Institute’s Uveitis Support Community) for shared experiences and coping strategies.

Work and travel considerations

Ensure you have a letter from your physician stating the need for regular medication refills and possible visual impairment. Carry eye drop bottles in your hand luggage when flying, and consider a portable cooler for biologic agents that require refrigeration.

Prevention

While you cannot prevent the underlying autoimmune disease, you can reduce the risk of uveitis flares and complications:

• Maintain strict control of the systemic autoimmune condition with disease‑modifying therapy.
• Adhere to steroid‑sparing regimens to minimize long‑term steroid side effects.
• Regular ophthalmic screening for at‑risk patients (e.g., annual eye exams for HLA‑B27 positive individuals).
• Quit smoking and limit alcohol, both of which can aggravate inflammation.
• Use protective eyewear in environments with dust, chemicals, or bright UV exposure.
• Promptly treat ocular infections, as they can trigger secondary inflammation.

Complications

If inflammation is not adequately controlled, several sight‑threatening complications may develop:

• Glaucoma: Elevated intra‑ocular pressure from inflammation or steroid use.
• Cataract: Posterior subcapsular cataracts are common with chronic steroid therapy.
• Macular edema: Fluid accumulation in the central retina, leading to central vision loss.
• Retinal neovascularization & vitreous hemorrhage.
• Band keratopathy: Calcium deposition on the cornea.
• Permanent vision loss: Up to 20% of chronic uveitis patients become legally blind if untreated (WHO, 2020).

When to Seek Emergency Care

---

References: Mayo Clinic. “Uveitis.” 2023; American Academy of Ophthalmology. “Uveitis Preferred Practice Pattern.” 2023; CDC. “Behçet’s Disease.” 2022; National Institutes of Health. “HLA‑B27 and Ankylosing Spondylitis.” 2022; WHO. “Global Vision Impairment Statistics.” 2020; FDA. “Adalimumab (Humira) Prescribing Information.” 2021.

```